؉ -T-cell response to Moloney murine leukemia virus (M-MuLV)-associated antigens in C57BL/6 mice is directed against an immunodominant gag-encoded epitope (CCLCLTVFL) presented in the context of H-2D b and is restricted primarily to cytotoxic T lymphocytes (CTL) expressing the V␣3.2 and V␤5.2 gene segments. We decided to examine the M-MuLV response in congenic C57BL/6 V␤ a mice which are unable to express the dominant V␣3.2 ؉ V␤5.2 ؉ T-cell receptor (TCR) due to a large deletion at the TCR locus that includes the V␤5.2 gene segment. Interestingly, M-MuLV-immune C57BL/6 V␤ a mice were still able to reject M-MuLV-infected tumor cells and direct ex vivo analysis of peripheral blood lymphocytes from these immune mice revealed a dramatic increase in CD8
Cytotoxic T lymphocytes (CTL) play an important role in the eradication of intracellular pathogens. CTL become activated when their T-cell receptors (TCR) specifically recognize foreign antigen in the form of a molecular complex between a major histocompatibility complex (MHC) class I molecule and a short antigenic peptide (31, 33) . TCR molecules are heterodimers whose ␣ and ␤ chains are composed of a constant (C) and a variable (V) extracellular domain. Somatic recombination of a number of V, diversity (D), and junctional (J) gene segments, imprecise joining, and addition of N nucleotides are responsible for the TCR␣-and -␤-chain diversity which is further increased by combinatorial ␣-␤ pairing (38) . The specificity of the TCR is determined mainly by three hypervariable complementarity-determining regions (CDR) of the ␣ and ␤ chains. CDR1 and CDR2 are encoded by V segments, whereas CDR3 is encoded by J elements for the ␣ chain and by D and J elements for the ␤ chain. This exceptional potential diversity (estimated at more than 10 15 for TCR) allows CD8 T cells to respond to a wide variety of antigens (14) .
Recent studies have focused on the diversity of TCR in recognizing one given antigen (9) . For example, TCR expressed by CTL clones specific for a single Plasmodium berghei circumsporozoite peptide were highly diverse in terms of V␣, J␣, and J␤ segments and amino acid compositions of the junctional regions. However the V␤ segment utilization was strongly conserved among the different clones (10) . In contrast, analysis of the TCR repertoire of CTL directed against a peptide derived from the human class I MHC molecule HLA-CW3 presented by murine MHC class I (H-2K d ) molecules at the surface of P815 tumor cells revealed a very limited heterogeneity both in terms of V␣, J␣, V␤, and J␤ segments and in terms of lengths and sequences of both CDR3␣ and -␤ (8) . This highly restricted TCR usage allowed the identification of antigen-specific T cells in individual immune DBA/2 mice either by staining with monoclonal antibodies (MAbs) to the V␤ domain (25) or by single-cell PCR (26) . In addition, V␤ preferences have been demonstrated in CD8 ϩ T-cell responses to acute infection by several viruses, including human immunodeficiency virus (30) , simian immunodeficiency virus (12) , Epstein-Barr virus (7) and lymphocytic choriomeningitis virus (24) .
In a previous publication (5), we showed that the CD8 ϩ T cells responsible for the rejection of Moloney murine leukemia virus (M-MuLV)-induced tumor cells had a very restricted usage of both V␣ and V␤ gene segments. Indeed, immunization of C57BL/6 (B6) mice with M-MuLV-induced tumor cells (MBL-2) led to an overwhelming expansion of CD8 ϩ T cells that recognized exclusively a virally encoded immunodominant epitope. This epitope (CCLCLTVFL), presented by H-2D b , is shared by leukemia and lymphoma cell lines infected by the Friend-Moloney-Rauscher (FMR) group of leukemia viruses and is encoded in the leader sequence of the gag polypeptide (11, 22) . These M-MuLV gag-specific CD8 ϩ T cells could be readily monitored ex vivo by flow cytometry since the majority coexpressed the V␣3.2 and V␤5.2 gene segments.
In the present study, we were interested in analyzing the 
Immunizations. M-MuLV-infected MBL-2 (H-2
b ) tumor cells were maintained by weekly passage in syngeneic B6 mice (6) . For primary immunization, 40 ϫ 10 6 irradiated (10,000 rads) tumor cells were injected intraperitoneally into syngeneic mice. After 3 to 4 weeks, secondary responses were elicited by intraperitoneal injection of 10 ϫ 10 6 viable syngeneic tumor cells. MLTC and CTL clones. Virus-specific CTL were generated in vitro in a 5-day mixed lymphocyte-tumor cell culture (MLTC) (3) . Responder spleen cells (25 ϫ 10 6 ) from M-MuLV immune mice and irradiated MBL-2 cells (1 ϫ 10 6 ) were cocultured in 15 ml of Dulbecco modified Eagle medium (Gibco, Paisley, United Kingdom) supplemented with 2 ϫ 10 Ϫ3 M L-glutamine, 2 ϫ 10 Ϫ2 M HEPES, 3 ϫ 10 Ϫ5 M 2-mercaptoethanol, antibiotics, and 5% heat-inactivated fetal calf serum (Irvine Scientific, Santa Ana, Calif.). Cells recovered from MLTC were washed and restimulated with irradiated MBL-2 and syngeneic feeder cells for a further seven days in complete medium supplemented with 30 U of interleukin 2 (EL-4 cell supernatant) per ml. CTL clones were established by plating cells from an MLTC at limiting dilution as described previously (5) .
Cytotoxic assays. CTL clones derived from M-MuLV-immune mice were used as effector cells. Target cells were either MBL-2 lymphoma (M-MuLV infected,
The FMR gag-encoded epitope CCLCLTVFL (11) was synthesized and purified by standard procedures and dissolved in dimethyl sulfoxide supplemented with ␤-mercaptoethanol. For cytotoxic assays, effector cells and 51 Cr-labeled target cells were mixed at the ratios indicated below in the presence or absence of various concentrations of peptide. Supernatants were harvested after 4 h, and specific 51 Cr release was calculated as described previously (5) .
Flow microfluorometry. At various times after primary or secondary immunization with syngeneic M-MuLV-infected tumor cells, mice were bled by the tail vein and peripheral blood lymphocytes (PBL) were isolated by Ficoll-Hypaque gradient centrifugation (Pharmacia Biotech, Uppsala, Sweden).
Four-color analyses of isolated PBL from M-MuLV-immune mice were performed with MAbs to CD8 (53-6.7), CD4 (RM4-5), and CD62L (Mel-14) and a panel of anti-V␤ MAbs including V␤2 (B20.6), V␤3 (KJ25), V␤4 (KT4), V␤5 (MR9-4), V␤6 (44-22), V␤7 (TR310), V␤14 (14-2), and V␤17 (KJ23) in conjunction with a panel of anti-V␣ MAbs including V␣2 (B20.1), V␣3.2 (RR3-16), V␣8 (B21.14), and V␣11 (RR8-1). CTL clones or MLTCs were triple stained with MAbs to CD8, V␤, and V␣. All samples were gated on viable cells (assessed by light scatter) and run on either a FACSCalibur or a FACStar (Becton Dickinson, San Jose, Calif.) equipped with either CellQuest or LYSIS II software, respectively.
RNA extraction, cDNA synthesis, and PCR. Total RNA was extracted from 5 ϫ 10 6 cells from MLTCs or CTL clones with QIAshredder columns as the cell lyzate homogenizer and an RNeasy Mini Kit as the RNA extraction system (both from Qiagen AG, Basel, Switzerland). Single-stranded cDNA synthesis was carried out on total RNA with oligo(dT)15 and avian myeloblastosis virus reverse transcriptase (Boehringer Mannheim Biochemicals, Indianapolis, Ind.). PCR was carried out in 50 l on 2/50 of the cDNA with 5 U of Taq polymerase (Eurobio) according to the manufacturer's instructions. Oligonucleotides for the PCR amplification were the following: (V␣3) 5Ј-AAGTACTATTCCGGAGAC CC-3Ј, (C␣a) 5Ј-TGGCGTTGGTCTCTTTGAAG-3Ј, (C␣b) 5Ј-ACACAGCAG GTTCTGGGTTC-3Ј, (V␤3) 5Ј-CCTTGCAGCCTAGAAATTCAGTCC-3Ј, (V␤5.2) 5Ј-AAGGTGGAGAGAGACAAAGGATTC-3Ј, (V␤17) 5Ј-GAACAA ACAGACTTGGTCAAG-3Ј, (C␤a) 5Ј-CCAGAAGGTAGCAGAGACCC-3Ј, and (C␤b) 5Ј-CTTGGGTGGAGTCACATTTCTC-3Ј (10). Forty cycles, each of 94°C for 15 s, 58°C for 45 s, and 72°C for 60 s, were completed in a thermocycler. PCR products were purified with a QIAquick PCR Purification Kit (Qiagen AG).
Sequencing reactions. Sequencing reactions of purified PCR products were done by fluorescent cycle sequencing with a Thermo Sequenase fluorescencelabeled primer cycle sequencing kit (Amersham Life Science Ltd.) according to the manufacturer's instructions and analyzed in a LI-COR DNA sequencer (MWG-biotech, Munchenstein, Switzerland).
RESULTS
TCR V␣ and V␤ repertoires of M-MuLV-immune B6.V␤ a mice. B6.V␤ a mice were injected with irradiated syngeneic M-MuLV-infected (MBL-2) tumor cells and boosted 2 weeks later with viable cells. Immune mice were able to reject the tumor. These mice were then bled at day 7 after the second injection, and PBL were pooled and stained with a panel of anti-V␣ or anti-V␤ MAbs together with anti-CD4 or anti-CD8 MAb. MAbs against CD62L (Mel-14) were included in the fourth color to increase the sensitivity of detection of responding CD8 ϩ or CD4 ϩ cells and to be able to differentiate between activated (CD62L Ϫ ) and nonactivated (CD62L other V␣ and V␤ domains tested showed lower levels in the CD62L Ϫ compartment than in the CD62L ϩ subset. As expected, no preferential TCR V␣ or V␤ usage was observed among the nonactivated (CD62L (Fig. 3B) . Interestingly, these immune mice were still able to reject the tumor and showed a significant expansion of CD62L Ϫ CD8 ϩ cells (data not shown). These results suggest that other TCR molecules can be utilized by B6.V␤ a mice in order to respond to M-MuLV-infected cells.
Absolute magnitude of the M-MuLV-specific CD8
؉ -T-cell response in immune B6.V␤ a mice. Since these experiments were performed by analyzing antigen-specific cells via fourcolor staining, it was possible to calculate the absolute magnitudes of the different subsets of M-MuLV-specific CD8 ϩ cells at the peak of the response in immune B6.V␤ a mice. V␣3.2 ϩ V␤3 ϩ CD62L Ϫ cells accounted on average for 0.5% of the CD8 subset and 0.05% of total PBL in these mice, whereas the proportions observed in naive animals were, respectively, Ͻ0.05% and Ͻ0.01%. The absolute number of V␣3.2 ϩ V␤17 ϩ CD62L Ϫ cells was even higher, since 5% of the CD8 subset and 0.05% of PBL in immune mice had this phenotype compared to Ͻ0.1% and Ͻ0.01%, respectively, in naive mice. It is important to point out that significant variations from mouse to mouse were observed. Fig. 4 Ϫ CD8 ϩ PBL decreased slowly over time but remained elevated for at least 150 days after immunization (Fig. 5B) (Fig. 6B) .
Sequencing of TCR from seven V␣3.2 ϩ V␤5.2 ϩ CTL clones revealed a dramatic conservation in both the ␣ and ␤ junctional regions (Fig. 6A) . Of 50 J␣ gene segments, only one (J␣13) was utilized by all the clones and even by CTL derived from two independent bulk cultures (MLTC I and II). In addition, analysis of the ␤ junctional regions of these CTL clones revealed the utilization of only one J␤ gene segment (J␤1.4). This restricted junctional usage was highlighted by the fact that both the CDR3␣ and CDR3␤ regions were totally conserved among the different clones, with an 8-amino-acid sequence (TPTSGGNY) for CDR3␣ and a 10-amino-acid sequence (SLVGGGNERL) for CDR3␤.
We then made the same analyses of seven B6.V␤ a -derived CTL clones. TCR␣ junctional region analysis revealed that again only one J␣ was utilized by V␤3 ϩ or V␤17 ϩ clones; however, this segment (J␣6) was different from that used by V␤5.2 ϩ CTL clones (Fig. 6B) . The CDR3␣ regions were in general strongly conserved among these CTL clones. We found a 9-amino-acid CDR3␣ consensus sequence, with only some differences in the second and third amino acids (SXX-SNTNKV). In contrast, TCR␤ junctional sequences of B6.V␤ a mice-derived clones revealed major differences from B6 micederived clones. First, V␤3 ϩ or V␤17 ϩ CTL clones utilized three different J␤ gene segments (J␤1.2, J␤2.4, and J␤2.6), and second, the CDR3␤ region was much less conserved, with different lengths (from 6 to 11 amino acids) and no consensus sequence. 
DISCUSSION

The CD8
ϩ -T-cell response to M-MuLV (and, in general, FMR)-associated antigens in B6 mice is directed against an immunodominant gag-encoded epitope (CCLCLTVFL) and is restricted primarily to CTL expressing the V␤5.2 and V␣3.2 gene segments (5) . The rationale of the experiments presented here was to examine the M-MuLV response in congenic B6.V␤ a mice which are unable to express the dominant V␣3.2 ϩ V␤5.2 ϩ TCR due to a large deletion at the TCR␤ locus that includes the V␤5.2 gene segment. Interestingly, B6.V␤ a mice were still able to reject M-MuLV-infected tumor cells and CTL from these immune mice utilized the same V␣3.2 gene segment in association with two different V␤ segments (V␤3 and V␤17). Surprisingly, these CTL recognized the same immunodominant M-MuLV gag epitope. The fact that the same H-2D b -restricted gag-encoded peptide CCLCLTVFL is recognized by V␤3 ϩ and V␤17 ϩ , as well as V␤5. . However, recognition of the modified peptide by CTL is greatly diminished (4a). The mechanism underlying the immunodominance of the gag epitope in H-2 b mice remains to be established. In this respect the hydrophobic nature of the peptide (which is encoded in the leader sequence of the gag polyprotein) or its putative ability to be efficiently processed may play a role.
Although CTL clones specific for the immunodominant FMR gag epitope were readily elicited in both B6 and B6.V␤ residue is located within the CDR1␤ domain of the V␤3 segment and thus might be expected to influence TCR recognition of the M-MuLV gag peptide by CD8 ϩ cells since (i) the CDR1␤ region has been shown to contact the C-terminal residues of the antigenic peptide in crystallographic studies of TCR-MHC class I-peptide complexes (17) (18) (19) , (ii) CDR1␤ polymorphism in the V␤10 gene segment has a dramatic influence on TCR recognition of the immunodominant H-2K d -restricted HLA-CW3 epitope by CD8 ϩ T cells (4) , and (iii) CDR1␤ polymorphism of V␤3 has already been shown to dramatically affect TCR recognition of a dominant pigeon cytochrome c peptide by MHC class II-restricted CD4 ϩ T cells (16) . Thus, the failure of M-MuLV-immune CTL from V␤ b mice to use V␤3 or V␤17 is due to structural differences in these gene segments between the V␤ a and V␤ b alleles rather than an intrinsic preference for utilization of V␤5.2 within the V␤ b haplotype. In order to directly compare the levels of utilization of V␤3, V␤5.2, and V␤17 in the CD8 ϩ -T-cell response to the M-MuLV gag epitope, we used (B6 ϫ B6.V␤ a )F 1 mice in which all three V␤ domains are expressed. Analysis of the TCR repertoire of individual F 1 mice revealed a clear hierarchy in V␤ utilization. Thus, V␤17 was used most frequently by responding CD8 ϩ
CD62L
Ϫ cells whereas V␤3 (and especially V␤5.2) were used to much lesser extents. Several possible explanations for this hierarchal V␤ usage can be considered. First, it is possible that V␤17-bearing TCR have a higher affinity for the M-MuLV gag peptide than V␤3-or V␤5.2-bearing TCR. Although difficult to test directly, this explanation is, however, not supported by the comparable peptide dose-response curves of gag-specific CTL clones expressing V␤17, V␤3, or V␤5.2. Second, it is possible that CD8 ϩ T cells expressing V␤17 ϩ gag-specific TCR arise more frequently than V␤3 ϩ or V␤5.2 ϩ TCR with the same specificity, perhaps due to differential positive selection in the thymus. In this respect it is interesting that V␤17 and V␤3 chains of gag-specific TCR were quite heterogeneous in J␤ usage and CDR3 sequence but that V␤5.2 chains were highly conserved (see below). These sequence data raise the possibility that V␤17 ϩ and V␤3 ϩ TCR recognizing the gag peptide are more frequent than gag-specific V␤5.2 ϩ TCR in the naive CD8 ϩ -T-cell population. Clearly, more direct experiments using MHC class I gag peptide tetramers in association with limiting dilution experiments will be required to address this issue.
Sequence analysis of the TCR␣ and -␤ chains utilized by CTL clones specific for the M-MuLV gag epitope revealed several important differences in the V␤ a and V␤ b haplotypes. Strikingly, TCR␣ and -␤ chains were absolutely conserved in V␤ b mice, since all CTL clones analyzed utilized V␣3.2-J␣13 and V␤5.2-J␤1.4 with completely conserved CDR3␣ and CDR3␤ regions. These conserved TCR␣ and -␤ chains were representative of the M-MuLV-specific V␤ b CTL population as a whole, since identical V␣3.2-J␣13 and V␤5.2-J␤1.4 junctional sequences were obtained by PCR from two independent polyclonal MLTC populations. In contrast, the TCR repertoires of M-MuLV gag-specific V␤ a CTL clones were considerably more diverse. In particular, the TCR␣ chain was again strikingly conserved, with all V␤ a CTL clones utilizing V␣3.2-J␣6 and a highly conserved (although not identical) CDR3␣ region. However, the TCR␤ chains of V␤ a CTL clones were much more diverse, since the two V␤ domains used (V␤3 and V␤17) were associated with three distinct J␤ segments and diverse CDR3␤ sequences.
These TCR sequence data are of interest in the context of a on August 27, 2017 by guest http://jvi.asm.org/ model proposing that the diversity of the TCR repertoire in response to a given foreign epitope is dependent upon the extent of homology between that epitope and self-determinants (9) . According to this model, a consequence of selftolerance will be that foreign epitopes that are highly homologous to self-peptides will elicit a restricted TCR repertoire but that epitopes unrelated to self will elicit a diverse TCR repertoire. In contrast, the data presented here indicate that the M-MuLV gag epitope CCLCLTVFL, which is not highly homologous to any expressed protein sequence (including endogenous retroviral leader sequences) in current databases (data not shown), can elicit a diverse repertoire of TCR␤ chains in V␤ a mice and a highly restricted ␤-chain repertoire in V␤ b mice. Since these congenic mouse strains differ only at the V␤ locus itself, it seems probable that the diversity of the ␤-chain repertoire in this instance is determined by the availability of V␤ segments rather than by the extent of tolerance imposed by self-homology of the peptide epitope.
Finally, the finding that several structurally distinct TCR are able to recognize the same M-MuLV-encoded gag peptide associated with H-2D b is consistent with growing evidence that TCR specificity is intrinsically highly cross-reactive or degenerate (27) . Indeed, a recent crystallographic study has demonstrated that the same peptide-MHC complex can be recognized by two distinct TCR in the same orientation despite the fact that almost all the individual peptide-MHC contact residues differ (15) . Conversely, a single TCR can recognize a wide variety of distinct peptide-MHC complexes with apparent high affinity, as in the case of the widely studied 2C TCR (34, 35) . Whether such TCR degeneracy reflects selection by a common self-peptide in the thymus during development (21) remains to be established.
